ClinicalTrials.gg
RecruitingNCT06868797ARCADIA-HFUpdated Sep 11, 2025

Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List

An interventional study of Biological sample for the measurement of suPAR levels. in Heart Failure, sponsored by Central Hospital, Nancy, France. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-11.

Sponsored by Central Hospital, Nancy, France · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
103
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Heart Failure by Central Hospital, Nancy, France — 9 open to participants now, 10 under way, 1 of them phase 3. Heart Failure · Central Hospital, Nancy, France.

Planned enrollment
7th of 13
103 · median 103
Started
2025
with 1 other
No phase
12 of 19
8 open now
Registered
17th of 19
by date

Among the 19 studies in Heart Failure by Central Hospital, Nancy, France, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 with no phase, and was the 17th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

9 of the 19 studies in Heart Failure by Central Hospital, Nancy, France are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Heart Failure by Central Hospital, Nancy, France, or all of them as a file.
02

Study summary

Heart failure affects 1 to 2% of the adult population in developed countries, representing about 55 million people worldwide.

Advanced heart failure is a condition where the heart can no longer provide sufficient cardiac output or equilibrate pressures within its chambers, leading to symptoms such as shortness of breath, fatigue, and water and salt retention.

Heart failure affects the kidneys by reducing blood flow directed to them, sometimes leading to kidney congestion. In the long term, this can degrade kidney function. Common medications used to treat heart failure, such as diuretics, can sometimes worsen kidney failure. This link between the heart and the kidneys is known as cardio-renal syndrome and requires careful management of both organs to prevent mutual degradation.

Dapagliflozin is an SGLT2 inhibitor medication used to treat type 2 diabetes, heart failure, and certain kidney diseases. It helps reduce blood sugar, improve heart and kidney function, while promoting the elimination of excess salt and water.

However, there are limited data regarding the progression of cardio-renal interactions in patients with advanced heart failure. Yet, advanced heart failure is often associated with kidney dysfunction.

The protein called suPAR is found in the blood of patients developing kidney disease and/or during the onset of acute kidney injury. This protein will allow to characterize a population of patients with advanced heart failure receiving optimized medical treatment, including dapagliflozin.

The main objective of this research is to assess, based on the suPAR protein level in the blood, the progression of cardio-renal damage between inclusion and 6 months in patients with advanced heart failure who are listed for a heart transplant and treated with a therapy including dapagliflozin.

The study plans 5 visits over 12 months. The research will take place in the cardiology department of several French hospitals.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 85 years
  2. class ≥3
  3. ≤ 35%
  4. On GDMT (including dapagliflozin) based on current heart failure practice guidelines at maximal tolerated dose
  5. On waiting list (or on the registration pathway) for heart transplantation after multidisciplinary Heart Team decision, with anticipated access to heart transplant ≥ 6 months or in a pre-transplant pathway.
  6. Person affiliated to a social security scheme or beneficiary of such a scheme.
  7. A person who has received full information about the organization of the clinical research and has signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Priority patient on waiting list for heart transplantation.
  2. Etiology of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy.
  3. Inotrope dependent, existence of ongoing mechanical circulatory support
  4. Current acute decompensated HF or hospitalization due to decompensated HF \<30 days prior to the enrolment.
  5. History of any organ transplant or prior implantation of a ventricular assistance device (VAD) or similar device, or implantation expected after inclusion.
  6. Any recent interventional procedure likely to improve symptoms and heart failure status (coronary revascularization, percutaneous mitral valve intervention, cardiac resynchronization therapy) \< 60 days.
  7. \<25 ml/min/1.73 m2, according to CKD-EPI formula
  8. Unstable or rapidly progressing renal disease (autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis).
  9. Type 1 diabetes mellitus.
  10. Participation in another clinical interventional trial.
  11. Any condition other than heart failure that could limit survival to less than 12 months.
  12. Pregnant women or breastfeeding mothers
  13. vulnerable persons (guardianship, curatorship, safeguard of justice)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
103 participants (estimated)

Study arms

  • Other
    Patients followed for end-stage heart failure

    Patients followed for end-stage heart failure and waiting for heart transplantation. This cohort will focus on cardio-renal assessment of advanced HF patients treated with optimal pharmacologic therapy including dapagliflozin. The biological material and clinical data collected will allow us to better understand the advanced HF and to generate new research hypotheses.

    Other: Biological sample for the measurement of suPAR levels.

Interventions

  • OtherBiological sample for the measurement of suPAR levels.

    Biological sample for the measurement of plasminogen activator receptor (suPAR) level at baseline and at 6 months follow up to assess the evolution of cardio-renal interaction in HF patients listed for heart transplant treated by GDMT including dapagliflozin.

06

What researchers measure

Primary outcomes

  1. the change in soluble urokinase-type plasminogen activator receptor (suPAR) levels (ng/ml)

    the change in soluble urokinase-type plasminogen activator receptor (suPAR) levels (ng/ml) between the baseline and 6 months of follow-up.

    Time frame: baseline and 6 months of follow-up.

Secondary outcomes

  1. VO2 max

    Functional status at baseline and 6 months assessed by VO2 max assessment

    Time frame: baseline and 6 months of follow-up.

  2. Delta GFR estimated by CKD-EPI formula (ml/min/1.73m²)

    The following parameters are collected at baseline to identify predictive factors associated with secondary endpoint. These parameters should not be considered as endpoints themselves: * Hemodynamic Parameters: cardiac output (L/min), pulmonary capillary wedge pressure (mmHg), pulmonary artery systolic and mean pressure (mmHg), right atrial pressure (mmHg). * Echocardiographic Parameters: LVEF (%), mitral regurgitation grade (0-4), left atrial volume (mL /m2). * Biological Parameters: Nt-proBNP (ng/L), Creatinine (µmol/L), GFR evaluate by Iohexol clearance (ml/min) or other method (ml/min) (inuline, EDTA chrome51 (51Cr EDTA), Iothalamate clearance),plasma volume calculated from haemoglobin (g/L) and haematocrit,(%) bilirubin (µmol/L), AST (UI/L), ALT (UI/L), kalemia (mmol/L), cystatin C (mg/L), sST2 (ng/mL), gremlins 1(pg/mL), FGF 23 (C terminal and intact) (pg/mL). * Congestion Markers: Clinical, biological, echocardiographic, and hemodynamic markers.

    Time frame: baseline and 6 months of follow-up.

  3. Rate of composite outcome (hospitalization for acute heart failure or all cause death).

    The following parameters are collected at baseline to identify predictive factors associated with secondary endpoint. These parameters should not be considered as endpoints themselves: * Hemodynamic Parameters: cardiac output (L/min), pulmonary capillary wedge pressure (mmHg), pulmonary artery systolic and mean pressure (mmHg), right atrial pressure (mmHg). * Echocardiographic Parameters: LVEF (%), mitral regurgitation grade (0-4), left atrial volume (mL /m2). * Biological Parameters: Nt-proBNP (ng/L), Creatinine (µmol/L), GFR evaluate by Iohexol clearance (ml/min) or other method (ml/min) (inuline, EDTA chrome51 (51Cr EDTA), Iothalamate clearance),plasma volume calculated from haemoglobin (g/L) and haematocrit,(%) bilirubin (µmol/L), AST (UI/L), ALT (UI/L), kalemia (mmol/L), cystatin C (mg/L), sST2 (ng/mL), gremlins 1(pg/mL), FGF 23 (C terminal and intact) (pg/mL). * Congestion Markers: Clinical, biological, echocardiographic, and hemodynamic markers.

    Time frame: 6 months of follow-up.

  4. Quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: baseline and 12 months.

  5. Global Leadership Initiative on Malnutrition criteria (GLIM Criteria)

    To assess changes in nutritional status according to Global Leadership Initiative on Malnutrition criteria status between Baseline and 6 months. Categories : no malnutrition, moderate malnutrition, or severe malnutrition

    Time frame: baseline and 6 months

  6. Daily food and nutrient intake

    The food frequency questionnaire evaluate the frequency of consumption and portion size for 170 foods, we then calculate the daily food intake (in g/day). Nutritrional values are determined by converting food intake into nutrient intake using a french food composition table. Each item can have a minimum intake of 0, with quantities varying based on the specific food and individual consumption.

    Time frame: baseline or the month following baseline

  7. cardiovascular death

    To assess incidence of cardiac and renal adverse events.

    Time frame: 12 months

  8. unplanned hospitalization for Heart failure

    To assess incidence of cardiac and renal adverse events. The definition for unplanned heart failure hospitalization requires: 1) a hospital stay for worsening heart failure for \>24 h; and 2) administration of intravenous or mechanical heart failure therapies, especially loop diuretics 3) heart failure symptoms/signs.

    Time frame: 12 months

  9. worsening of Heart failure

    To assess incidence of cardiac and renal adverse events. The definition for worsening of heart failure requires an administration of loop diuretics intravenous (ambulatory or home-care) due to a worsening of heart failure symptoms/signs.

    Time frame: 12 months

  10. cardiac transplantation

    To assess incidence of cardiac and renal adverse events

    Time frame: 12 months

  11. ECMO

    To assess incidence of cardiac and renal adverse events

    Time frame: 12 months

  12. Left Ventricular Assist Device

    To assess incidence of cardiac and renal adverse events

    Time frame: 12 months

  13. Delisting from national waiting list

    to assess incidence of cardiac and renal adverse events

    Time frame: 12 months

  14. renal death

    To assess incidence of cardiac and renal adverse events.

    Time frame: 12 months

  15. chronic dialysis

    To assess incidence of cardiac and renal adverse events.

    Time frame: 12 months

  16. renal transplantation

    To assess incidence of cardiac and renal adverse events.

    Time frame: 12 months

  17. End stage renal disease

    To assess incidence of cardiac and renal adverse events. Chronic dialysis, renal transplantation or sustained eGFR \<15 mL/min/1.73m²

    Time frame: 12 months

  18. worsening cardio-renal syndrome

    To assess incidence of cardiac and renal adverse events. Worsening cardio-renal syndrome was defined according to the Kidney Disease Improving Global Outcomes (KIDGO) criteria as a ≥ 26.5 µmol/L (0.3mg/dL) increase in serum creatinine or 1.5-1.9 times baseline increase in serum creatinine or a urine output \<0.5 ml/kg/h for 6-12 hours.

    Time frame: 12 months

  19. GFR estimated by CKD-EPI formula (serum creatinine cystatin or both)

    To assess the degree of agreement between the different methods of estimating GFR.

    Time frame: baseline and 6 months

  20. GFR estimated by MDRD formula

    To assess the degree of agreement between the different methods of estimating GFR.

    Time frame: baseline and 6 months

  21. urinary creatinine (renal functional assessment (BFR))

    To assess the degree of agreement between the different methods of estimating GFR.

    Time frame: baseline and 6 months

  22. iohexol clearance

    to assess the degree of agreement between the different methods of estimating GFR

    Time frame: baseline and 6 months

  23. inuline clearance

    To assess the degree of agreement between the different methods of estimating GFR

    Time frame: baseline and 6 months

  24. EDTA chrome51

    To assess the degree of agreement between the different methods of estimating GFR

    Time frame: baseline and 6 months

  25. Iothalamate clearance

    To assess the degree of agreement between the different methods of estimating GFR

    Time frame: baseline and 6 months

  26. PLAUR gene expression

    To assess the change in gene expression (including PLAUR gene) using the RNA collected at baseline and at 6 months.

    Time frame: baseline and 6 months

07

Study locations

1 of 11 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 17 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Mar 11, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Sep 12, 2027
Last update
Sep 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06868797
Responsible party
BAUDRY Guillaume (coordinating investigator, Central Hospital, Nancy, France) — Principal investigator
First posted
Mar 11, 2025
Start date
Aug 29, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Sep 12, 2027 (estimated)
Last update
Sep 11, 2025

Study contacts

Guillaume BAUDRY, MD
Contact
g.baudry@chru-nancy.fr
+33 (0) 383157322
Nicolas GIRERD, MD-PhD
study chair · CHRU de NANCY

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion